Malara, Angela Eliana (2010) Effects of three different anti-ErbB2 antibodies on prostate tumors. [Tesi di dottorato] (Inedito)


Download (691kB) | Anteprima
[error in script] [error in script]
Tipologia del documento: Tesi di dottorato
Lingua: English
Titolo: Effects of three different anti-ErbB2 antibodies on prostate tumors
Malara, Angela
Data: 29 Novembre 2010
Numero di pagine: 30
Istituzione: Università degli Studi di Napoli Federico II
Dipartimento: Biologia strutturale e funzionale
Scuola di dottorato: Scienze biologiche
Dottorato: Biochimica e biologia cellulare e molecolare
Ciclo di dottorato: 23
Coordinatore del Corso di dottorato:
De Lorenzo,
Data: 29 Novembre 2010
Numero di pagine: 30
Parole chiave: ErbB2-Prostate cancer
Settori scientifico-disciplinari del MIUR: Area 05 - Scienze biologiche > BIO/10 - Biochimica
Depositato il: 09 Dic 2010 16:49
Ultima modifica: 17 Giu 2014 06:02


Prostate cancer is the most commonly diagnosed malignancy in men in developed countries. ErbB2 contributes to prostate cancer progression by activating the androgen receptor in a steroid poor environment, thus promoting androgen-independent cell growth and survival. The consequent development of hormone refractory tumors is a major obstacle in prostate cancer therapy. The inhibition of ErbB2 signal transduction pathways by the use of human antibodies has been considered as a valuable alternative strategy for cancer therapy. Herein we report a comparative analysis of the antitumor effects of three different antibodies targeting different epitopes of ErbB2: Herceptin (Trastuzumab), 2C4 (Pertuzumab), and Erb-hcAb, a novel fully human compact antibody produced in our laboratory. We demonstrate that the in vitro and in vivo growth of both androgen- dependent and –independent prostate cancer cells is efficiently inhibited by Erb-hcAb, which shows antitumor effects on some cell lines more potent than those observed for either Herceptin or 2C4

Actions (login required)

Modifica documento Modifica documento